Positive outlook for innovation-driven Pharma and Biotech sectors

INNOVATION will continue to drive the pharma and biotech sectors in 2015 as forecasts point to another prosperous year, according to the latest report, “Pharma & Biotech 2015 Preview”, from EP Vantage, the editorial arm of market intelligence firm Evaluate Ltd.

Key findings:

• A dozen products due to be launched next year are forecast to achieve blockbuster sales by 2020.
• Drugs treating high cholesterol and heart failure will dominate the field with a combined 2020 sales forecast of $8 billion.
• Sovaldi and its combination product Harvoni will take the No. 1 worldwide seller spot with forecast sales of $15.3 billion in 2015.
• Patent expiries will have minimal impact on the top line as 2015 sales will grow close to four times that of patent losses.
• Financing climate appears friendly and deals will continue at a steady pace but M&A activity is unlikely to match the frenzy of 2014.

“Cancer will also have a huge year as the promise of immuno-oncology therapies are further tested,” said Amy Brown, EP Vantage reporter and report author. “But with payers looking to restrain drug prices, marketed products may face heightened commercialization risks. Nonetheless, if 2015 lives up to today’s heady expectations, it will be a remarkable year that the sector will long remember.”

Pharma & Biotech 2015 Preview is based on market intelligence and consensus forecasts from EvaluatePharma®